LAVAL, QC, May 12, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today reported revenues of $5.2 million for the first quarter ended March 31, 2016 compared to $1.9 million for the first quarter ended March 31, 2015.
"We are pleased to see our total revenues and product sales off to a good start for the year", said Mr. Greg Weaver, Chief Financial Officer of ProMetic. "The combination of the Structured Alpha follow-on financing and $60 million bought deal recently announced puts the Corporation in a great position to continue building a strong pipeline of therapeutics", added Mr. Weaver.
"The clinical data generated so far in both our small molecule and plasma derived therapeutic programs has validated our selection of lead compounds and clinical indications to be first pursued", stated Mr. Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. "It also provides us with very valuable clinical information and confidence in our ability to continue delivering positive clinical efficacy data going forward in additional related clinical programs", added Mr. Laurin.
First Quarter 2016 Highlights
Small Molecule Therapeutics:
Other significant developments after the quarter
More on First Quarter 2016 Financial Results
The financial information for the first quarter ended March 31, 2016 should be read in conjunction with the Corporation's condensed interim consolidated financial statements as well as the Management's Discussion and Analysis for the quarter ended March 31, 2016.
Total revenues for the quarter ended March 31, 2016 were $5.2 million compared to $1.9 million for the quarter ended March 31, 2015. The revenues from the sale of goods amounted to $4.7 million for the first quarter of 2016 compared to $1.4 million for the first quarter of 2015.
Research and development expenses were $16.5 million for the quarter ended March 31, 2016 compared to $9.8 million for the quarter ended March 31, 2015. The increase is mainly due to the overall increase in research and development activities both in the protein technologies and the small molecules therapeutics segments reflecting the increase in the number of trials in progress, the continuing development of additional therapeutics and the continued efforts towards the filing of future IND.
Administration, selling and marketing expenses totaled $4.8 million for the quarter ended March 31, 2016 compared to $3.3 million for the quarter ended March 31, 2015. The increase is mainly attributable to the increase in compensation expense resulting from an increase in headcount over the one year period and the related increase in operating costs.
The Corporation incurred a net loss of $18.0 million during the quarter ended March 31, 2016 compared to a net loss of $20.4 million for the corresponding period of 2015. The net loss in 2015 was higher since it was affected by a loss on the fair value of the warrant liability of $3.4 million and a loss on extinguishment of liabilities of $6.1 million which were not repeated in 2016. However during the first quarter of 2016, the operating expenses were significantly higher than those in the first quarter of 2015, namely in R&D. Finally, ProMetic closed the quarter ended March 31, 2016 with a cash position of $34.5 million.
Additional Information in Respect to the First Quarter ended March 31, 2016
ProMetic's MD&A and condensed interim consolidated financial statements for the quarter ended March 31, 2016 have been filed on SEDAR (http://www.sedar.com/) and will be available on the Corporation's website at www.prometic.com.
About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.
Forward Looking StatementsThis press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward -looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2015, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
Subscribe to our Free Newsletters!
Endoscopic Retrograde Cholangio-Pancreatography uses endoscopy and fluoroscopic imaging for ...
Wolff-Parkinson-White syndrome is caused due to an extra electrical pathway in the heart, which ...
Discover the amazing health benefits of this ''under-valued'' vegetable called leek. Know the ...View All